Parkinson’s disease is a chronic degenerative neurological disorder affecting millions globally. Its manifestation — the death of dopaminergic cells in the substantia nigra — leads to motor dysfunction, encompassing symptoms like shaking, rigidity, and gait abnormalities, as well as potential non-motor symptoms, including cognitive dysfunction. At PsychoGenics, our goal is to enable you to identify groundbreaking treatments for this debilitating disease. 

Capabilities in Preclinical Parkinson’s Disease Research 

PsychoGenics boasts a wide array of capabilities, including the use of transgenic mouse models and advanced tools that uncover the potential impact of your therapy: 

This model, developed in collaboration with the Michael J. Fox Foundation, enables us to induce propagation of α-synuclein by striatal injection of mouse preformed α-synuclein fibrils. α-synuclein is a key pathological feature of PD and contributes to disease progression.

We have licensed Line 61, an α-synuclein transgenic mouse model expressing human α-synuclein cDNA. This model presents many of the key characteristics of human Parkinson’s disease, including lack of coordination and the presence of α-synuclein histopathology.

This model involves the injection of 6-OHDA into the rat striatum and medial forebrain bundle, resulting in the dramatic and permanent loss of dopaminergic neurons in the substantia nigra and subsequent motor deficits. This model has been used to assess neuroprotective agents and symptomatic treatments.

In this model, systemic administration of the neurotoxin MPTP induces PD-like signs, including the loss of striatal dopamine nerve terminals and dopamine neuron death in the substantia nigra.

Validated Non-Genetic Animal Models  

We employ validated non-genetic animal models to further our understanding of Parkinson’s disease and assess potential neuroprotective agents. 

Your Preclinical Parkinson’s Disease Research Partner 

At PsychoGenics, our comprehensive approach, advanced models, and strategic collaborations drive breakthroughs in preclinical Parkinson’s disease research. Together, let’s change patient outcomes and forge the path to transformative therapies. 

Partner with us and transform your program


Get Started